Glaukos Corporation (GKOS)

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Glaukos Corporation GKOS reported record fourth-quarter 2024 revenues of $105.5 million, reflecting a 28% year-over-year increase. This growth was driven by strong demand for its innovative glaucoma a...

On Monday, Glaukos Corporation GKOS received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Ep...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.

Glaukos Corporation (NYSE:GKOS ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President, Investor Relations and Corporate Affairs Tom Burns - C...

Glaukos (GKOS) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.63 per share a year ago.

Here is a sneak peek into how three MedTech stocks, GKOS, ITGR and AMN, are expected to fare in their quarterly results, slated to be released tomorrow.

Beyond analysts' top -and-bottom-line estimates for Glaukos (GKOS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter...

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.